1. Academic Validation
  2. Discovery and Characterization of BAY-184: A New Potent and Selective Acylsulfonamide-Benzofuran In Vivo-Active KAT6AB Inhibitor

Discovery and Characterization of BAY-184: A New Potent and Selective Acylsulfonamide-Benzofuran In Vivo-Active KAT6AB Inhibitor

  • J Med Chem. 2024 Nov 14;67(21):19282-19303. doi: 10.1021/acs.jmedchem.4c01709.
Antonius Ter Laak 1 Roman C Hillig 1 Steven J Ferrara 2 Daniel Korr 1 Naomi Barak 1 Philip Lienau 1 Simon Herbert 1 Amaury Ernesto Fernández-Montalván 1 Roland Neuhaus 1 Mátyás Gorjánácz 1 Vera Puetter 1 Volker Badock 1 Wilhelm Bone 1 Craig Strathdee 2 Franziska Siegel 1 Christoph Schatz 1 Katrin Nowak-Reppel 1 Olaf Doehr 1 Stefan Gradl 1 Ingo V Hartung 1 Matthew Meyerson 2 Léa Bouché 1
Affiliations

Affiliations

  • 1 Bayer AG, Pharmaceuticals, Research and Development, Müllerstrasse 178, Berlin 13353, Germany.
  • 2 Broad Institute of MIT and Harvard, Center for the Development of Therapeutics, 415 Main St., Cambridge, Massachusetts 02142, United States.
Abstract

KAT6A and KAT6B genes are two closely related lysine acetyltransferases that transfer an acetyl group from acetyl coenzyme A (AcCoA) to lysine residues of target histone substrates, hence playing a key role in chromatin regulation. KAT6A and KAT6B genes are frequently amplified in various Cancer types. In breast Cancer, the 8p11-p12 amplicon occurs in 12-15% of cases, resulting in elevated copy numbers and expression levels of chromatin modifiers like KAT6A. Here, we report the discovery of a new acylsulfonamide-benzofuran series as a novel structural class for KAT6A/B inhibition. These compounds were identified through high-throughput screening and subsequently optimized using molecular modeling and cocrystal structure determination. The final tool compound, BAY-184 (29), was successfully validated in an in vivo proof-of-concept study.

Figures
Products